Ependymoma Treatment with Maintenance Chemotherapy – Phase III

ACNS0831: Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma

Protocol Description

This Children’s Oncology Group clinical trial is studying maintenance chemotherapy to see how well it works following induction chemotherapy and radiation therapy in treating young patients with newly diagnosed ependymoma, a type of slow-growing brain tumor.

Study Level: Phase III

Eligibility Criteria

Subject to certain exclusion criteria, this study is open to both males and females, ages 1 to 21 years, who will have had surgery for their ependymoma prior to participation.
Males and Females: Ages 1 to 21 years


Based on the extent of tumor removal patients will be placed in various therapy arms including observation, chemotherapy, or radiotherapy arms. Those receiving chemotherapy arm will receive a short course of induction chemotherapy administered intravenously. Specific features of the tumor and its reaction to chemotherapy will determine next steps. Some participants may require a second surgery followed by observation with or without chemotherapy.
Visits: Varies depending on randomization arm
Duration: 7 to 25 weeks, depending on outcomes

Status: Open for Enrollment

Source(s) of Support

Children’s Oncology Group (Study ACNS0831)
National Cancer Institute

Primary Investigator

Jean Tersak, MD

Contact Information

For more information about the study or enrollment, please contact:
Research Coordinator Angela Krol, RN, BSN